ArticleFrontiers in cell and developmental biology2026
A mechanistic study on the enhanced antihypertensive effects of a
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In our previously published research, we reported that the combination of Dendrobium Officinale Compound (DOC) and antihypertensive medications (irbesartan and amlodipine besylate) significantly and stably regulates blood pressure in spontaneously hypertensive rats (SHRs). This study aims to further explore the unique mechanisms and pathway networks underlying the antihypertensive effects of this combination therapy at the molecular level, based on serum and ileocecal contents metabolomics as well as gut microbiota analysis. Methods: Utilizing UPLC-Q-TOF/MS and metabolomics techniques, we collected, analyzed, and integrated metabolite data to identify differential small molecule metabolites. High-throughput sequencing of the 16S rRNA gene was employed to characterize differences in gut microbiota composition among experimental animals subjected to distinct pharmacological interventions, and further elucidating the underlying antihypertensive mechanism network associated with the combined administration of DOC and conventional antihypertensive drugs. Results: Metabolomic analyses revealed substantial differences in the profiles of low-molecular-weight metabolites in both serum and ileocecal contents across all treatment groups compared with the model control group. The antihypertensive effects of medium- and high-dose DOC in SHRs were associated with differential metabolites including L-tyrosine, L-methionine, and L-arginine; in contrast, the enhanced antihypertensive effect observed upon combination therapy with DOC and Western antihypertensive drugs correlated with distinct metabolites such as pregnenolone, creatine, and L-phenylalanine. 16S rRNA gene high-throughput sequencing of ileocecal contents indicated that the relative abundance of Firmicutes increased by 8.73%, 0.84%, and 10.40% following low-, medium-, and high-dose DOC interventions, respectively, relative to the model group; however, combination therapy with DOC and Western antihypertensive drugs resulted in an 8.80% decrease in Firmicutes abundance compared with the model group. Conversely, the relative abundance of Bacteroidetes decreased by 7.60%, 3.31%, and 7.67% after low-, medium-, and high-dose DOC treatments, respectively, versus the model group; yet, combination therapy led to a 7.05% increase in Bacteroidetes abundance relative to the model group. Conclusion: Metabolomic and 16S rRNA sequencing analyses revealed that these effects may be linked to DOC's specific modulation of serum amino acid profiles and remodeling of gut microbiota composition in PCAs. These findings provide new mechanistic insights into this traditional herb's antihypertensive action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.